CARB-X is a non-profit partnership

CARB-X is funded by the Wellcome Trust in the United Kingdom, the United States Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR), and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). CARB-X operates through Boston University. The UK Government’s Department of Health and Social Care (DHSC), through its Global Antimicrobial Resistance Innovation Fund (GAMRIF) has been a CARB-X funding partner since May 2018. The Bill and Melinda Gates Foundation, the world’s largest foundation dedicated to improving the quality of life for individuals around the world, is a CARB-X Alliance Partner since May 2018. CARB-X accelerators include the California Life Sciences Institute (CLSI), RTI International, the Broad Institute of Harvard and MIT, MassBio, and the Defense Threat Reduction Agency (DTRA), part of the US Department of Defense. With funds from its Funding and Alliance Partners, CARB-X is investing more than $500 million from 2016-2021 to accelerate the development of innovative antibiotics and other therapeutics, vaccines, rapid diagnostics and devices to address drug-resistant bacterial infections.


UK Government

Alliance Partners

Bill and Melinda Gates Foundation


Boston University
Broad Institute


BARDA is a core component of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR). BARDA draws on its extensive experience of successfully advancing promising medical countermeasures through late-stage development. BARDA is providing CARB-X with up to $250 million during the 2016-2021 program.

Wellcome Trust

Wellcome Trust is one of the world’s leading funders of biomedical R&D, with significant experience and commitment in antibacterial R&D. Wellcome is funding CARB-X with up to $155 million to CARB-X between 2016-2021. Tim Jinks and Ed Whiting represent the Wellcome Trust on the JOC.


NIAID is a US Government agency and is a key funder to protect against emerging infectious diseases, including antimicrobial resistance. NIAID commits in-kind services (e.g. preclinical services) to projects supported by CARB-X over five years and retains key governance roles.Dennis Dixon and Ann Eakin represent NIAID on the JOC.

The UK Government’s Department of Health and Social Care (DHSC), Global Antimicrobial Resistance Innovation Fund (GAMRIF)

The Department for Health and Social Care (DHSC) is the UK Government department which is responsible for helping people to live more independent, healthier lives for longer. The partnership with CARB-X is part of DHSC’s Global Antimicrobial Resistance Innovation Fund (GAMRIF). GAMRIF was established to provide seed funding for innovative research and development, specifically in neglected and underinvested areas, to address the threat of AMR. GAMRIF is a £50m UK aid investment, which means all projects funded must support research which is primarily and directly for the benefit of people in low- and middle-income countries (LMICs).

Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation is a major funder of global health R&D. The foundation is partnering with CARB-X to advance the development of vaccines and novel biologics to avert drug-resistant diseases and protect the lives of vulnerable populations in low- and middle-income countries.

Boston University

Boston University Law is one of the nation’s leading law schools, with prominent programs in health care and intellectual property law. Boston University is the home of CARB-X, led by a distinguished executive team:

Kevin Outterson, Executive Director
Barry Eisenstein, Chair of the Scientific and Business Advisory Board
Karen Gallant, Global Project Director
Rich Lawson, Senior Project Manager

RTI International

RTI International, an independent, nonprofit institute headquartered in the Research Triangle Park in North Carolina, will provide research support services to product developers in the partner accelerators as well as build and run the computing systems to identify, track and monitor all research programs, including a real-time dashboard management information systems. RTI will evaluate all CARB-X operations, sharing best practices across all partners and supporting continuous quality improvement.

California Life Sciences Institute

Located in one of the world’s most innovative and productive biotech hubs, this accelerator has extensive experience nurturing start-ups towards Series A financing and beyond. Since start-ups often fail for business reasons unrelated to science, this partner will provide world-class business support and mentoring services to innovative product developers selected for funding.


MassBio was the first biotechnology trade association formed in the US, and is located in Cambridge, MA at the epicenter of the Massachusetts life sciences innovation hub. Since its founding in 1985, MassBio has cultivated a preeminent life sciences knowledge base and talent network, and has renowned experience accelerating innovation through the MassCONNECT and Pharma Days programs. MassBio will provide business support and mentoring services to CARB-X companies.

Broad Institute

The Broad Institute is one of the world’s most innovative non-profit research centers will create an inter-disciplinary Collaborative Hub for Early Antibiotic Discovery (CHEAD) with a goal of advancing at least three therapeutic products through shared chemistry services. CHEAD will be led by Dr. Deborah Hung, a Core Institute Member at the Broad and a co-director of its infectious disease program.